EBF
EBF
EBF
European
Bioanalysis
Forum


EBF vzw is the registered non-profit organisation of the European Bioanalysis Forum

 

 

YSS Slides 2020

PDF renditions of the PowerPoint presentations can be viewed and downloaded from this page by clicking the specific point on the program. The program itself can be viewed and downloaded by clicking here.

Program details of the EBF 6th YSS

24 September 2020
11:30 13:00 If local site can host 2 days: a local welcome
13:00 13:15 Welcome – coming online
13:15 14:00 Session 1: Is non-standard the new standard?
13:15 13:30 Connor Walker (Arcinova)
Non-standard technique in a regulated environment: what considerations come with it?
13:30 13:45 Salvatore Calogero (Swiss BioQuant)
FACS in the bioanalysis
13:45 14:00 Eugenia Hoffmann (F. Hoffmann-La Roche)
Impact of drug/anti-drug antibody complexes on drug pharmacokinetics: advanced bioanalysis for a better understanding of immunogenicity
Parallel session
14:30 15:45 Parallel Session 2: Rethinking Matrix
14:30 14:45 Michele Protti (Unibo)
Unraveling details and potentials of VAMS technique: towards the raise of a new golden standard
14:45 15:00 Camilla Marasca (Unibo)
Novel microfluidic-based sampling for therapeutic drug monitoring of patients under treatment with the antidepressant drug vortioxetine
15:00 15:15 Virginia Brighenti (University of Modena and Reggio Emilia)
New Analytical Tools for the Study of Bioactive Polyphenols in Prunus avium L. (sweet cherry) and Evaluation of their Anti-oxidant Activity on an In vivo Model.
15:15 15:30 Maaike Bruin (The Netherlands Cancer Institute (NKI))
Development and validation of an LC-MS/MS method with a broad linear dynamic range utilizing natural isotopologue transitions for quantification of tivozanib
15:30 15:45 Jana Verstraete (UGent)
The simultaneous quantification of thiamine, its phosphate derivatives and precursors in Arabidopsis thaliana: validation and application.
14:30 15:45 Parallel Session 3: ADApting
14:30 14:45 Sam Wilcox (Covance)
Biosimilar ADA assessments using the Gyrolab platform
14:45 15:00 Fanni Suomi (Syrinx Bioanalytics)
Concentration analysis and immunogenicity testing of next generation oligonucleotides and targeted delivery molecules
15:00 15:15 Cara Gunning (Charles River Laboratories)
Approaches to Improve Drug Tolerance in Immunogenicity Assays
15:15 15:30 Zoe Whiffen (LGC)
Anti-PEG: past, present and future difficulties in a regulated environment
15:30 15:45 Adam Williams (AstraZeneca)
Development of a method for detection of anti-drug antibodies against the PEG component of a lipid nanoparticle drug product
16:30 17:30 Session 4: Before we digest….let’s digest.
16:30 16:45 Bas Sleumer (PRA Health Sciences)
The differences between digested and intact protein analysis: determination of somatropin in rat plasma.
16:45 17:00 Lisa Delahaye (UGent)
Determination of paracetamol-albumin adducts via LC-HRMS
17:00 17:15 Terence Hetzel (Bayer)
Determination of thorium-conjugated monoclonal antibody from monkey plasma by different LC-MS technologies
17:30 for those staying overnight – enjoy the evening whilst keeping social distance
25 September 2020
09:00 10:30 Site dependent local activities
10:30 12:00 Science Café: A Sustainable Future
Format: round table
During this session we want to engage you how we can contribute to a sustainable future.
This includes e.g. stimulating or applying the 3Rs (Replacement, Reduction and Refinement) and/or the principles of green lab/chemistry…
We are preparing a dynamic round table discussion where all of you can contribute.
12:30 13:30 Interactive poster viewing
13:45 14:15 Plenary Feedback from local Science Café round tables: A Sustainable Future
14:30 15:45 Session 5: It’s what’s inside that counts
14:30 14:45 Coral Munday (LGC)
Fit-for-Purpose Validation: A Non-Standard Approach for a Non-Standard Biomarker Assay
14:45 15:00 Mondanelli Giada (University of Perugia)
Indoleamine 2,3-dioxygenase 2 as new biomarker of tumor progression
15:00 15:15 Malleswari Challagundla (AbbVie)
Development and validation of alpha-synuclein aggregation assay using surrogate matrix
15:15 15:30 Tessa McDonald (Unilabs York Bioanalytical Solutions)
Qualifying the measurement of endogenous and synthetic spiked pharmacodynamic biomarker in matrix, in the presence of drug
16:00 17:15 Session 6: Compete to Collaborate!
16:00 16:15 Rob Stewart (Covance)
Investigating generic PK methods of quantifying human monoclonal antibodies in pre-clinical species by LC-MS and ligand-binding assays.
16:15 16:30 Chris Williams (QPS Netherlands)
Hybrid LC-MS ligand binding assays for bioanalysis
16:30 16:45 Rebecca Paterson (Charles River Laboratories)
Antibody Drug Conjugate Bioanalysis – An opportunity for LBA and LC-MS Synergy?
16:45 17:00 Closing Remarks and Adjourn